AOD 9604 Dosage & Side Effects Guide

Research protocols follow body weight tiers. These doses come from community protocols and original clinical trial parameters, not from FDA-approved prescribing guidelines (none exist).

Timing. AOD 9604 is administered on an empty stomach, typically first thing in the morning. Insulin blunts AOD 9604's lipolytic activity because the peptide's mechanism depends on a low-insulin metabolic state. Wait at least 30 minutes before eating.

Split-dose protocol. Some protocols divide the daily dose: 250 mcg in the morning (fasted) and 250 mcg before bed (at least 3 hours after last meal). This approach maintains more consistent beta-3 receptor activation throughout the day.

Cycle length. Research protocols run 12 weeks (matching the Phase 2b trial duration). Some extend to 16 weeks. A 4-6 week off period between cycles is commonly recommended to prevent receptor desensitization.

Use our unit converter for dose calculations and see the peptide dosage chart for comparison with other peptides.

AOD 9604 ships as a lyophilized (freeze-dried) powder. Standard reconstitution uses bacteriostatic water.

Standard preparation: 5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL

Alternative concentration: 5 mg vial + 1 mL bacteriostatic water = 5,000 mcg/mL (smaller injection volume, but harder to measure precise doses on standard syringes).

Steps: 1. Wipe both the vial stopper and bacteriostatic water vial with alcohol swabs. 2. Draw 2 mL of bacteriostatic water into a syringe. 3. Insert the needle into the AOD 9604 vial and let the water run down the inside wall. 4. Gently swirl the vial. Never shake peptides. 5. Wait until the powder dissolves completely (1-3 minutes).

Storage: Refrigerate at 2-8C. Use within 28-45 days after reconstitution. Do not freeze reconstituted peptides.

For detailed instructions, use our reconstitution calculator and see our guide on bacteriostatic water vs sterile water. For injection technique, see how to inject peptides.

AOD 9604 is a 16-amino acid peptide derived from the C-terminal fragment of human growth hormone (residues 176-191). The key structural modification: a tyrosine residue replaces phenylalanine at the N-terminal, which preserves fat-metabolizing activity while eliminating growth-promoting effects.

Beta-3 adrenergic receptor activation. AOD 9604 upregulates beta-3 adrenergic receptor (beta-3 AR) expression on fat cells, triggering a cAMP signaling cascade that activates hormone-sensitive lipase. This enzyme breaks stored triglycerides into free fatty acids for energy use. Knockout mouse studies confirmed this pathway: beta-3 AR knockout mice were completely unresponsive to AOD 9604 (Heffernan et al., 2001, Endocrinology, PMID: 11713213).

Lipogenesis inhibition. AOD 9604 simultaneously reduces the rate at which excess calories convert to stored fat. In obese Zucker rats, 500 mcg/kg reduced weight gain by more than 50% (Ng et al., 2000, Hormone Research, PMID: 11146367).

Visceral fat selectivity. Animal data suggests particular efficacy on visceral adipose tissue, the metabolically dangerous fat surrounding organs.

Serum half-life. AOD 9604 has a very short serum half-life of approximately 4 minutes. This sounds limiting, but the peptide triggers sustained enzyme activation that continues after the peptide itself clears. This is why once-daily dosing produces measurable effects despite the short circulating half-life.

What it does NOT do. Unlike full HGH, AOD 9604 does not activate the IGF-1 pathway. No IGF-1 elevation means no blood sugar disruption, no cell proliferation risk, and no growth-related side effects. This was confirmed across all six clinical trials (Heffernan et al., 2001, International Journal of Obesity, PMID: 11673763).

No other dosage guide covers both the Phase 2a success and Phase 2b failure with this level of detail. Understanding both is essential for informed decision-making.

Phase 2a trial (positive results). Metabolic Pharmaceuticals enrolled 300 obese subjects across 5 Australian trial sites for 12 weeks. Six dose arms tested oral AOD 9604 at 1 mg, 5 mg, 10 mg, 20 mg, and 30 mg against placebo.

The 1 mg result looked promising. Metabolic Pharmaceuticals' stock surged on the announcement.

Phase 2b / OPTIONS study (failed). The larger confirmatory trial enrolled 536 obese patients for 24 weeks with oral dosing at 1 mg, 5 mg, and 10 mg.

The trial failed its primary endpoint. None of the AOD 9604 groups showed statistically significant weight loss compared to placebo. Development was terminated in 2007.

The oral bioavailability question. All human trials used oral administration. Peptide oral bioavailability is typically below 1%. AOD 9604 is unusual: animal data shows approximately 40% oral bioavailability (Ng et al., PMID: 11146367). Subcutaneous injection achieves near-100% bioavailability. Injectable AOD 9604 has never been tested in a controlled human trial. Community use is primarily subcutaneous, a different route than what was clinically tested. This is the critical gap in the evidence.

Safety across all 6 trials (~900 subjects). No treatment-related serious adverse events. No clinically significant adverse events. No anti-AOD9604 antibodies detected (immunogenicity negative across all subjects tested). No IGF-1 changes. Adverse event profile indistinguishable from placebo (Stier et al., Journal of Endocrinology and Metabolism).

In six randomized, double-blind, placebo-controlled trials involving approximately 900 adults, AOD 9604's adverse event profile was indistinguishable from placebo.

What AOD 9604 does NOT cause (confirmed in clinical data):

• No blood sugar changes. Unlike full HGH, AOD 9604 does not affect glucose metabolism.
• No IGF-1 elevation. "AOD9604 had no effect on serum IGF-1 levels" across all trials.
• No antibody formation. Immunogenicity testing was negative in all subjects tested across 6 trials.
• No water retention. Unlike full HGH, which causes significant edema in many users.
• No insulin resistance. Full HGH is diabetogenic; AOD 9604 is not.
• No cortisol or HPA axis changes.

Contraindications and cautions:

• Pregnancy and breastfeeding (no safety data exists)
• Active cancer (theoretical concern with any growth-hormone-derived compound)
• Under 18 years old (no pediatric data)
• Concomitant full HGH use (redundant pathways, no additive benefit expected)
• Athletes in WADA-tested competition (prohibited substance)

The safety profile is the strongest argument for AOD 9604. The weakness is on the efficacy side, not the safety side. For comparison with other fat-loss approaches, see our tesamorelin dosage guide and sermorelin guide.

This is the most common comparison question. The honest answer: semaglutide has vastly superior evidence.

AOD 9604's advantages are limited to three areas: lower side effects, lower cost, and no appetite suppression (some users prefer maintaining normal appetite). For patients seeking proven pharmaceutical fat loss, semaglutide and tirzepatide are backed by large randomized controlled trials showing 15-22% weight loss.

See our semaglutide dosage chart and tirzepatide dosage chart for FDA-approved weight loss medication dosing. Compare costs with our cost calculator.

An overlooked secondary application supported by animal research and Australian regulatory approval.

Kwon and Park (2015) tested intra-articular AOD 9604 combined with hyaluronic acid in a rabbit osteoarthritis model. The combination enhanced cartilage regeneration significantly beyond either treatment alone. AOD 9604 stimulated chondrocyte proliferation and increased type II collagen production, the primary structural protein in articular cartilage (Annals of Clinical and Laboratory Science, PMID: 26275694).

The Australian Therapeutic Goods Administration (TGA) approved AOD 9604 for cartilage repair formulations, recognizing its chondroprotective properties separately from its failed fat-loss development.

This application uses intra-articular injection (directly into the joint), not the subcutaneous route used for fat loss. Dosing protocols for cartilage repair differ from the fat-loss protocols described above. No controlled human trial has confirmed cartilage repair efficacy.

For more on peptides used for joint recovery, see our best peptides for joint pain guide.

AOD 9604 can be combined with peptides that use different mechanisms. Verify combinations with our interaction checker and plan protocols with our stack calculator.

AOD 9604 + CJC-1295/Ipamorelin. Fat loss synergy through complementary pathways. AOD 9604 targets fat cells directly (beta-3 AR). CJC-1295 and Ipamorelin stimulate growth hormone release, which promotes fat metabolism through a different cascade. Timing: AOD 9604 in the morning (fasted), CJC/Ipamorelin before bed (to amplify natural nighttime GH pulse).

AOD 9604 + BPC-157. Fat loss combined with tissue repair. BPC-157 works through nitric oxide and growth factor pathways unrelated to beta-3 adrenergic receptors. No known interaction. Can be administered in the same syringe or separately.

AOD 9604 + Semaglutide. Complementary mechanisms: AOD 9604 targets fat cells directly while semaglutide suppresses appetite through GLP-1 receptors. No published interaction data suggests contraindication. This is a "belt and suspenders" approach.

AOD 9604 + HGH Fragment 176-191. Do not stack. AOD 9604 IS a modified version of HGH Frag 176-191. Both target the same beta-3 AR pathway. Combining them provides no additive benefit and wastes product.

AOD 9604 occupies a complicated and evolving regulatory space.

FDA 503A exclusion (2024). The FDA added AOD 9604 to the list of substances that cannot be compounded under Section 503A. Licensed compounding pharmacies in the United States cannot legally prepare AOD 9604 for individual patients. The FDA cited insufficient safety and efficacy data for therapeutic use.

PCAC advocacy (December 2024). The Pharmacy Compounding Advisory Committee heard testimony from advocates including Dr. Edwin Lee, who presented safety data from the 900-patient clinical dataset arguing that AOD 9604 should remain available for compounding. The committee's recommendation was advisory only.

GRAS status (2007). The FDA granted AOD 9604 Generally Recognized As Safe status as a food ingredient. This is NOT therapeutic approval. GRAS means it is safe to consume in food products at specified levels. Many sources incorrectly conflate GRAS food status with drug safety approval.

WADA prohibited. The World Anti-Doping Agency bans AOD 9604 under "Peptide Hormones, Growth Factors, Related Substances and Mimetics." Athletes face sanctions for positive tests.

Research chemical availability. AOD 9604 remains available from research suppliers labeled "for research use only." This gray market is where most users acquire the peptide. Research chemicals are not regulated as drugs and are technically not legal for human self-administration.

Australian TGA. In Australia, AOD 9604 was approved for cartilage repair formulations by the Therapeutic Goods Administration.

For the broader regulatory landscape, see our peptide legality guide and FDA peptide crackdown analysis.

AOD 9604 is the lowest-cost option with the weakest clinical evidence. Semaglutide and tirzepatide have FDA approval, large RCTs, and proven 15-22% weight loss. For proven pharmaceutical fat loss, GLP-1 drugs are the clear choice. AOD 9604 remains in the research conversation because of its favorable safety profile and low cost.

See our best peptides for weight loss guide for a comprehensive comparison.